About this trial
This study is a Phase III, global, randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients
Patient Profile
The target population for this study are Mayo Stage IV AL amyloid patients.
Where’s this trial being run?
Beaumont Hospital and Cork University Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | AFFIRM-AL |
|---|---|
| Number: | 22-13 |
| Full Title: | AFFIRM-AL: Global Phase 3 randomised double-blind trial of birtamimab plus standard of care vs placebo plus standard of care in Mayo Stage IV AL amyloid patients |
| Principal Investigator: | Dr John Quinn |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Prothena |
| Recruitment Started: |
Global: 30-Aug-2021 Ireland: TBC |
| Global Recruitment Target: | 150 |
|---|---|
| Ireland Recruitment Target: | 4 |